ALX/FPR2 (formyl peptide receptor 2) is a G-Protein Receptor that functions as the primary receptor for Lipoxins and multiple families of Specialized pro-resolving mediators (SPMs), playing a pivotal role in inflammatory resolution. This receptor exhibits biased agonism—different ligands binding to the same receptor can trigger either pro-inflammatory or pro-resolution signaling cascades depending on ligand structure and cellular context. Originally identified as a pattern recognition receptor, ALX/FPR2 serves as a master molecular switch determining whether inflammation progresses or resolves.
Imagine ALX/FPR2 as a sophisticated revolving door at a hospital entrance that can spin in two different directions. When bacterial debris or stress proteins (like Serum amyloid A) approach from outside, the door spins clockwise, ushering in emergency response teams—neutrophils rush to the site, inflammatory alarms sound, and the immune army mobilizes for battle. But when resolution signals like Lipoxins or Resolvins arrive, the same door spins counterclockwise, now bringing in the cleanup crews: macrophages that switch from fighters to janitors, collecting debris, turning off alarm systems, and starting tissue repair. The door itself hasn't changed—it's the same physical structure—but the direction it spins completely alters who enters and what happens inside the building. If the door gets stuck or loses sensitivity to resolution signals (as happens in chronic inflammation), the emergency teams keep arriving but the cleanup crews never show up, leaving the building in permanent chaos despite the threat being long gone.
ALX/FPR2 operates through distinct conformational states that activate different G-protein signaling cascades based on ligand binding:
Pro-inflammatory cascade (SAA/bacterial peptide binding):
SAA or formylated bacterial peptides → ALX/FPR2 → Gαi/o activation → phospholipase C (PLC) → IP3/DAG → Ca²⁺ release → PKC activation → NF-κB nuclear translocation → pro-inflammatory gene transcription (IL-8, TNF-α, IL-1β) + neutrophil chemotaxis via ERK1-2/PKA pathway
Pro-resolution cascade (SPM binding):
Lipoxins/RvD1/Annexin-1 (ANXA1) → ALX/FPR2 conformational change → Gαi2/3 preferential coupling → PKA → CREB phosphorylation → anti-inflammatory gene expression + PI3K/AKT pathway → NF-κB inhibition via IκB stabilization + ERK → Efferocytosis enhancement + neutrophil apoptosis signaling + macrophage phenotype switching (M1→M2) + nociceptor desensitization
SPM-specific downstream effects:
graph TD
A[ALX/FPR2 Receptor] --> B{Ligand Type?}
B -->|SAA/bacterial peptides| C["Gαi/o coupling"]
B -->|"SPMs: LXA4, RvD1, ANXA1"| D["Gαi2/3 coupling"]
C --> E[PLC activation]
E --> F["Ca²⁺ mobilization"]
F --> G["NF-κB activation"]
G --> H["Pro-inflammatory genes:<br/>IL-8, TNF-α, IL-1β"]
F --> I[Neutrophil chemotaxis]
D --> J[PKA activation]
J --> K[CREB phosphorylation]
K --> L[Anti-inflammatory genes]
D --> M[PI3K/Akt pathway]
M --> N["NF-κB inhibition via IκB"]
D --> O[ERK cascade]
O --> P[Efferocytosis enhancement]
O --> Q["M1→M2 macrophage switch"]
O --> R[Neutrophil apoptosis]
D --> S[Pain pathway modulation]
S --> T["↓TRPV1/TRPA1 in DRG"]
Receptor regulation:
- Expression upregulated during Lipid mediator class switching (COX-2/LOX ratio shift)
- Receptor density increases on macrophages during resolution phase
- Ligand binding triggers receptor internalization and recycling
- Chronic inflammatory mediators can downregulate ALX/FPR2 expression, impairing resolution capacity
ALX/FPR2 represents a critical therapeutic target in cPNI practice because it is the primary molecular gate controlling inflammatory resolution. This receptor's dysfunction directly explains why inflammation becomes chronic despite the absence of ongoing infection—the system has lost its ability to recognize and respond to stop signals.
Five Metamodel Integration:
- Metamodel 0 (Evolutionary mismatch): Modern low-omega-3 fatty acids diets (precursors for SPMs) reduce natural ALX/FPR2 agonist availability, while chronic stress maintains high Serum amyloid A levels, biasing the receptor toward pro-inflammatory signaling
- Metamodel 1 (Internal milieu): Chronic Low-Grade Inflammation downregulates ALX/FPR2 expression, creating a vicious cycle where tissues lose resolution capacity
- Metamodel 3 (Selfish systems): The Selfish Brain competes with peripheral tissues for omega-3 fatty acids needed to synthesize SPMs that activate ALX/FPR2
Relevant patient populations:
Clinical thresholds:
- Plasma RvD1 levels <0.5 ng/mL suggest insufficient ALX/FPR2 agonist availability
- Resolution interval (R_i) >48 hours indicates impaired resolution signaling (normal Ri: 24-36 hours)
- Neutrophil-to-lymphocyte ratio >3:1 with sustained elevation suggests inadequate ALX/FPR2-mediated neutrophil clearance
Intervention implications:
- Omega-3 fatty acids: EPA (2-3 g/day) and DHA (1-2 g/day) provide substrate for endogenous SPM synthesis
- Aspirin (low-dose): Acetylates COX-2 → aspirin-triggered Lipoxins (AT-LXA4) → ALX/FPR2 activation
- Resolution pharmacology: Emerging therapies using synthetic SPMs or ALX/FPR2 agonists to restore resolution capacity
- Address receptor downregulation: Reduce chronic inflammatory drivers (gut dysbiosis, chronic stress, metabolic syndrome) to restore ALX/FPR2 expression
- ALX/FPR2 binds >20 different ligands with opposing effects: pro-inflammatory (SAA, fMLF) vs pro-resolution (Lipoxins, Resolvins, Annexin-1 (ANXA1))
- Receptor affinity for LXA4: Kd ~1-5 nM; for RvD1: Kd ~0.5 nM (high-affinity binding)
- Expressed on neutrophils, macrophages, dendritic cells, endothelial cells, neurons, and fibroblasts
- Aspirin-triggered lipoxins (15-epi-LXA4) bind ALX/FPR2 with 2-3× higher affinity than native LXA4
- Activation reduces neutrophil transendothelial migration by 60-80% in experimental models
- ALX/FPR2-mediated Efferocytosis can clear >5 apoptotic cells per macrophage (vs <1 without receptor activation)
- Receptor expression increases 3-5 fold during the switch from acute inflammation to resolution phase
- In chronic pain, spinal ALX/FPR2 activation reduces mechanical allodynia by 40-60% in animal models
- Genetic variants affecting ALX/FPR2 function are associated with increased risk of atherosclerosis and chronic inflammation
- Receptor activation in dorsal root ganglia inhibits TRPV1 and TRPA1 channels, directly reducing pain signaling
- Specialized pro-resolving mediators (SPMs) — ALX/FPR2 serves as the principal receptor for multiple SPM families (lipoxins, resolvins, maresins), transducing their resolution signals into cellular responses
- Lipoxins — endogenous agonist with highest affinity for ALX/FPR2, initiating the resolution cascade and halting neutrophil recruitment
- Resolvins — RvD1, RvD3, RvD5 bind ALX/FPR2 to promote macrophage efferocytosis and reduce nociceptive signaling in chronic pain states
- Annexin-1 (ANXA1) — endogenous glucocorticoid-induced protein that activates ALX/FPR2 to mediate anti-inflammatory effects of cortisol
- aspirin — acetylates COX-2 enabling synthesis of 15-epi-lipoxins (aspirin-triggered lipoxins) that bind ALX/FPR2 with enhanced potency
- Efferocytosis — ALX/FPR2 activation enhances macrophage phagocytosis of apoptotic cells via PI3K/Akt pathway, critical for resolution completion
- NF-κB — ALX/FPR2 signaling through SPMs inhibits NF-κB nuclear translocation by stabilizing IκB, reducing inflammatory gene expression
- chronic inflammation — persistent inflammation downregulates ALX/FPR2 expression, creating resolution failure and chronic inflammatory states
- chronic pain — ALX/FPR2 activation in dorsal root ganglia and spinal cord reduces neuroinflammation and nociceptive sensitization via TRPV1/TRPA1 inhibition
- neutrophils — ALX/FPR2 on neutrophils stops chemotaxis (counter-regulatory signal to CXCR3/IL-8 receptors) and promotes apoptosis during resolution
- macrophages — receptor activation drives phenotypic switch from M1 (inflammatory) to M2 macrophages (repair), mediated by STAT3/6 pathways
- omega-3 fatty acids — DHA and EPA serve as metabolic precursors for resolvin/protectin synthesis, providing endogenous ALX/FPR2 ligands
- wound healing — ALX/FPR2 signaling coordinates timely transition from inflammatory to proliferative phase, essential for normal tissue repair
- Resolution interval (R_i) — ALX/FPR2 activation determines the duration and efficiency of resolution, with receptor dysfunction prolonging Ri
- RvD1 — potent ALX/FPR2 agonist (Kd ~0.5 nM) that reduces pain, enhances efferocytosis, and limits fibrosis in multiple disease models
- COX-2 — aspirin-modified COX-2 generates 15-epi-lipoxins that preferentially activate ALX/FPR2, explaining aspirin's resolution-promoting effects
- pain — ALX/FPR2 agonists reduce pain through both peripheral (inflammatory) and central (spinal/DRG) mechanisms, offering novel analgesic strategies
- atherosclerosis — defective plaque macrophage ALX/FPR2 signaling impairs efferocytosis of apoptotic foam cells, driving necrotic core expansion
- Lipid mediator class switching — during inflammation-to-resolution transition, cells upregulate ALX/FPR2 while downregulating leukotriene receptors, redirecting lipid mediator responses
- M2 macrophages — ALX/FPR2 activation promotes anti-inflammatory M2 polarization via IL-4/STAT6-independent pathways, supporting tissue repair
- Serum amyloid A — acute phase protein that acts as pro-inflammatory ALX/FPR2 agonist, demonstrating receptor's dual capacity for inflammation amplification vs resolution
- DHA — metabolic precursor for D-series resolvins (RvD1-6) that activate ALX/FPR2 to resolve inflammation and pain
- EPA — substrate for E-series resolvins (RvE1, RvE2, RvE3), with RvE1 activating both ALX/FPR2 and its own receptor to amplify resolution
- dorsal root ganglia — sensory neurons express ALX/FPR2; activation reduces nociceptor excitability and pain transmission to spinal cord
- atherosclerosis — endothelial ALX/FPR2 reduces monocyte adhesion and promotes regression of early atherosclerotic lesions when activated by resolvins
- Rheumatoid arthritis — synovial tissue shows reduced ALX/FPR2 expression and impaired resolvin responsiveness, contributing to chronic joint inflammation
- Inflammatory bowel disease — intestinal epithelial ALX/FPR2 mediates barrier restoration and mucosal healing; deficiency perpetuates IBD chronicity